QMS – Page 17 – Pharma.Tips

API change not reported during inspection preparation – PQ assessment risk and mitigation

Addressing Unreported API Changes During Inspection Preparation: A Comprehensive Playbook In the ever-evolving landscape of pharmaceutical manufacturing, effective communication regarding Active Pharmaceutical Ingredient (API) changes is crucial for maintaining compliance…

PQ dossier deficiency during WHO PQ assessment – CAPA expectations for PQ approval

Addressing PQ Dossier Deficiencies during WHO PQ Assessments: A Comprehensive Playbook for Pharma Professionals In today’s rapidly evolving pharmaceutical landscape, ensuring compliance with regulatory frameworks like the World Health Organization…

API change not reported during WHO PQ assessment – PQ assessment risk and mitigation

Mitigating Risks of Unreported API Changes during WHO PQ Assessments In the pharmaceutical industry, the integrity of Active Pharmaceutical Ingredients (APIs) is paramount, especially during the WHO Prequalification (PQ) assessments.…

API change not reported during WHO PQ assessment – CAPA expectations for PQ approval

Addressing Unreported API Changes During WHO PQ Assessments: A Practical Playbook In the fast-paced pharmaceutical manufacturing environment, maintaining compliance with WHO prequalification (PQ) standards is crucial for regulatory success. However,…

Manufacturing site not PQ-ready during dossier submission – PQ assessment risk and mitigation

Navigating PQ Readiness Challenges in Pharmaceutical Manufacturing Manufacturers often face risks when their production sites are not fully ready for PQ assessments during dossier submissions. This situation can significantly impact…

Stability data gaps during inspection preparation – CAPA expectations for PQ approval

Effective Solutions for Stability Data Gaps During Inspection Readiness for PQ Approval During the preparation for inspections related to WHO Prequalification (PQ) approval, the identification of stability data gaps can…

CAPA effectiveness doubted during WHO PQ assessment – preventing PQ suspension

Strategies to Ensure CAPA Effectiveness and Prevent Suspension During WHO PQ Assessments Manufacturers aiming for WHO Prequalification (PQ) face strict scrutiny that often casts doubt on the effectiveness of Corrective…

PQ dossier deficiency during inspection preparation – PQ assessment risk and mitigation

Addressing PQ Dossier Deficiencies for Successful Inspection Preparation In today’s pharmaceutical environment, the ability to prepare comprehensively for inspections is paramount. A deficiency in the PQ dossier can compromise not…

Manufacturing site not PQ-ready during inspection preparation – preventing PQ suspension

Ensuring Manufacturing Sites Are Prepared for PQ Inspections: A Playbook In the pharmaceutical industry, the inability of a manufacturing site to meet prequalification (PQ) standards prior to inspection can lead…

Manufacturing site not PQ-ready during dossier submission – how to defend manufacturing readiness

Defending Manufacturing Readiness When Your Site Isn’t PQ-Ready During Dossier Submission Pharmaceutical manufacturers often face stringent regulatory requirements, particularly during WHO Prequalification (PQ) submissions. An alarming finding can be a…

CAPA effectiveness doubted during WHO PQ assessment – documentation gaps reviewers flag

Ensuring CAPA Effectiveness During WHO Prequalification Assessments In the pharmaceutical industry, maintaining high standards of compliance is critical, especially during WHO Prequalification (PQ) assessments. Questions surrounding the effectiveness of Corrective…

Deviation history questioned during inspection preparation – how to defend manufacturing readiness

Preparing for Inspections When Your Deviation History is Under Scrutiny In the ever-evolving landscape of pharmaceutical manufacturing, the scrutiny of deviation history during inspections poses a substantial challenge. Regulatory authorities…